Indicators
Indicators
Value
Direction
MACD(12,26,9)
6.660
Buy
RSI(14)
71.659
Buy
STOCH(KDJ)(9,3,3)
88.657
Buy
ATR(14)
13.318
High Vlolatility
CCI(14)
181.326
Buy
Williams %R
0.720
Overbought
TRIX(12,20)
0.345
Sell
StochRSI(14)
100.000
Overbought
Search
Krystal Biotech Inc
KRYSAdd to Watchlist
305.710USD
+9.010+3.04%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
9.01BMarket Cap
39.46P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Krystal Biotech Inc
Currency: USD Updated: 2026-05-08Key Insights
Krystal Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 2 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 317.60.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Krystal Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Krystal Biotech Inc Highlights
StrengthsRisks
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 667.53% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 389.13M.
Fairly Valued
The company’s latest PE is 39.46, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.95M shares, decreasing 6.17% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 105.00 shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
309.300
Target Price
+1.17%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-08The current financial score of Krystal Biotech Inc is 9.37, ranking 2 out of 384 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 116.36M, representing a year-over-year increase of 31.95%, while its net profit experienced a year-over-year increase of 56.53%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.03
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.81
Krystal Biotech Inc's Company Valuation
Currency: USD Updated: 2026-05-08The current valuation score of Krystal Biotech Inc is 5.31, ranking 371 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is 39.46, which is 1028.84% below the recent high of 445.49 and 379.46% above the recent low of -110.29.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 2/384
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-08The current earnings forecast score of Krystal Biotech Inc is 8.67, ranking 71 out of 384 in the Biotechnology & Medical Research industry. The average price target is 218.00, with a high of 255.00 and a low of 198.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
309.300
Target Price
+1.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Krystal Biotech Inc
KRYS
12
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-08The current price momentum score of Krystal Biotech Inc is 9.64, ranking 6 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 323.88 and the support level at 269.75, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
292.584
Buy
MA10
279.319
Buy
MA20
275.153
Buy
MA50
264.040
Buy
MA100
265.077
Buy
MA200
221.294
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-08The current institutional shareholding score of Krystal Biotech Inc is 10.00, ranking 1 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 98.36%, representing a quarter-over-quarter decrease of 1.12%. The largest institutional shareholder is The Vanguard, holding a total of 2.74M shares, representing 9.31% of shares outstanding, with 4.63% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-08The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Krystal Biotech Inc is 8.08, ranking 6 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.48
VaR
+4.62%
240-Day Maximum Drawdown
+15.94%
240-Day Volatility
+43.47%
Return
Best Daily Return
60 days
+7.86%
120 days
+7.86%
5 years
+121.65%
Worst Daily Return
60 days
-7.28%
120 days
-7.28%
5 years
-19.55%
Sharpe Ratio
60 days
+1.43
120 days
+2.44
5 years
+0.75
Risk Assessment
Maximum Drawdown
240 days
+15.94%
3 years
+42.26%
5 years
+44.55%
Return-to-Drawdown Ratio
240 days
+9.06
3 years
+1.29
5 years
+1.90
Skewness
240 days
-0.55
3 years
+2.77
5 years
+13.16
Volatility
Realised Volatility
240 days
+43.47%
5 years
+66.26%
Standardised True Range
240 days
+2.65%
5 years
+1.91%
Downside Risk-Adjusted Return
120 days
+417.77%
240 days
+417.77%
Maximum Daily Upside Volatility
60 days
+32.06%
Maximum Daily Downside Volatility
60 days
+27.80%
Liquidity
Average Turnover Rate
60 days
+1.03%
120 days
+1.01%
5 years
--
Turnover Deviation
20 days
-7.02%
60 days
-6.09%
120 days
-7.79%
Peer Comparison
Biotechnology & Medical Research
Krystal Biotech Inc
KRYS
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AnaptysBio Inc
ANAB
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Veracyte Inc
VCYT
8.25 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
